These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 9808609)

  • 21. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
    Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T
    J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
    Latruffe N; Vamecq J
    Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
    Hughes TA; Stentz F; Gettys T; Smith SR
    Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of fibrates on serum metabolic parameters.
    Elisaf M
    Curr Med Res Opin; 2002; 18(5):269-76. PubMed ID: 12240789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
    Vu-Dac N; Schoonjans K; Kosykh V; Dallongeville J; Fruchart JC; Staels B; Auwerx J
    J Clin Invest; 1995 Aug; 96(2):741-50. PubMed ID: 7635967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-cholesterol agents, new therapeutic approaches].
    Fruchart JC; Duriez P
    Ann Pharm Fr; 2004 Jan; 62(1):3-18. PubMed ID: 14747768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.
    Guo L; Hu WR; Lian JH; Ji W; Deng T; Qian M; Gong BQ
    Eur J Pharmacol; 2006 Dec; 551(1-3):80-6. PubMed ID: 17026988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice.
    Mardones P; Pilon A; Bouly M; Duran D; Nishimoto T; Arai H; Kozarsky KF; Altayo M; Miquel JF; Luc G; Clavey V; Staels B; Rigotti A
    J Biol Chem; 2003 Mar; 278(10):7884-90. PubMed ID: 12511553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism.
    Fruchart JC
    Am J Cardiol; 2001 Dec; 88(12A):24N-29N. PubMed ID: 11788127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.
    Ziouzenkova O; Perrey S; Asatryan L; Hwang J; MacNaul KL; Moller DE; Rader DJ; Sevanian A; Zechner R; Hoefler G; Plutzky J
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2730-5. PubMed ID: 12606719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
    Ribas V; Palomer X; Roglans N; Rotllan N; Fievet C; Tailleux A; Julve J; Laguna JC; Blanco-Vaca F; Escolà-Gil JC
    Biochim Biophys Acta; 2005 Dec; 1737(2-3):130-7. PubMed ID: 16226489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP; Lemieux I; Robins SJ
    Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fibrates].
    Yamada N
    Nihon Rinsho; 2002 May; 60(5):962-7. PubMed ID: 12030000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.
    Hennuyer N; Poulain P; Madsen L; Berge RK; Houdebine LM; Branellec D; Fruchart JC; Fiévet C; Duverger N; Staels B
    Circulation; 1999 May; 99(18):2445-51. PubMed ID: 10318668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo.
    Mukherjee R; Strasser J; Jow L; Hoener P; Paterniti JR; Heyman RA
    Arterioscler Thromb Vasc Biol; 1998 Feb; 18(2):272-6. PubMed ID: 9484993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.
    Auwerx J; Schoonjans K; Fruchart JC; Staels B
    Atherosclerosis; 1996 Jul; 124 Suppl():S29-37. PubMed ID: 8831913
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.